Publications for Yaya Chu

NYMC School of Medicine
  • Ayello, J., Chu, Y., Keever-Taylor, C. A., Talano, J. A., Weinberg, R., Abikoff, C. M.,. . . Cairo, M. S. (2016). A pilot trial of unmatched human placenta-derived stem cells (HPDSCs) in conjunction with unrelated cord blood transplantation (UCBT) in children and young adults with malignant and non-malignant disease (IND 14949). Blood, 128(22), 4671.

  • Ayello, J., Chu, Y., Keever-Taylor, C. A., Talano, J. A., Weinberg, R., Abikoff, C. M., . . . Cairo, M. S. (2016). Familial haploidentical (FHI) allogeneic stem cell transplantation utilizing CD34 enrichment and T cell addback in children, adolescents & adults with high-risk sickle cell disease. Rapid engraftment, low incidence of AGVHD, and sustained donor chimerism. Blood, 128(22), 1245. 

  • Barth, M. J., Chu, Y., Hanley, P. J., & Cairo, M. S. (2016). Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. British Journal of Haematology, 173(4), 597-616. doi:10.1111/bjh.14078

  • Chu, Y., Brand, P., Morris, E., Lee, F., Talano, J. M., Shenoy, S., . . . Cairo, M. S. (2016). Natural killer cell reconstitution following familial haploidentical (FHI) CD34 enriched stem cell transplantation with T-cell add back in patients with high risk sickle cell disease (SCD) (IND 14359). Biology of Blood and Marrow Transplantation, 22(3), S151-S152. doi:10.1016/j.bbmt.2015.11.502

  • Chu, Y., Flower, A., & Cairo, M. S. (2016). Modification of expanded NK cells with chimeric antigen receptor mRNA for adoptive cellular therapy. Methods in Molecular Biology, 1441, 215-230. doi:10.1007/978-1-4939-3684-7_18

  • Chu, Y., Lee, F., Ayello, J., Hang, B., Zhang, M., Wong, H., . . . Cairo, M. (2016). Therapeutic effects of Alt-803, an IL-15 superagonist, in combination with anti-CD20 chimeric antigen receptor modified expanded natural killer cells against Burkitt lymphoma (BL). Cytotherapy, 18(6), S59. doi:10.1016/j.jcyt.2016.03.194

  • Chu, Y., Lee, F., Ayello, J., Hang, B., Zhang, M., Wong, H., . . . Cairo, M. S. (2016). Therapeutic effects of Alt-803, an IL-15 superagonist, in combination with anti-CD20 chimeric antigen receptor modified expanded natural killer cells against Burkitt lymphoma (BL). Biology of Blood and Marrow Transplantation, 22(3), S151. doi:10.1016/j.bbmt.2015.11.501

  • Chu, Y., Lee, F., Hamby, C., Misarti, J., Hang, B., Ayello, J., . . . Cairo, M. (2016). Regulation of cytokine release and anti-tumor effect of anti-CD20 CAR modified expanded natural killer cells by Alt-803, an IL-15 superagonist. Experimental Hematology, 44(9), S64. doi:10.1016/j.exphem.2016.06.107

  • Chu, Y., Yahr, A., Cheng, B., Hang, B., Ayello, J., Barth, M., & Cairo, M. S. (2016). Enhanced in-vitro and in-vivo targeting of rituximab sensitive and resistant Burkitt lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer cells in combination with a histone deacetylase inhibitor, romidepsin. Biology of Blood and Marrow Transplantation, 22(3), S392. doi:10.1016/j.bbmt.2015.11.915

  • Chu, Y., Yahr, A., Cheng, B., Hang, B., Ayello, J., Barth, M., & Cairo, M. S. (2016). Enhanced in-vitro and in-vivo targeting of rituximab sensitive and resistant Burkitt lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer cells in combination with a histone deacetylase inhibitor, romidepsin. Pediatric Blood & Cancer, 63(Suppl S1), S96.

  • Flower, A., Chu, Y., Ayello, J., Kurtzberg, J., Lee, D., & Cairo, M. S. (2016). Ex-vivo expansion of previously cryopreserved, thawed and re-cryopreserved cord blood mononuclear cells (CBMC) utilizing K562-mbIL21-41BBL; potential for adoptive cellular immunotherapy post umbilical cord blood transplantation (UCBT). Biology of Blood and Marrow Transplantation, 22(3), S153. doi:10.1016/j.bbmt.2015.11.504

  • Talano, J., Abikoff, C., Moore, T. B., Weinberg, R. S., Braniecki, S., Chu, Y., . . . Cairo, M. S. (2016). Familial haploidentical (FHI) allogeneic stem cell transplantation utilizing CD34 enrichment and T cell addback in children, adolescents & adults with high-risk sickle cell disease. rapid engraftment, robust immune reconstitution, low-incidence of GVHD. Pediatric Blood & Cancer, 63(Suppl 1), S93-S94.

  • Chu, Y., Hochberg, J., Yahr, A., Ayello, J., Van De Ven, C., Barth, M., . . . Cairo, M. S. (2015). Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunology Research, 3(4), 333-344. doi:10.1158/2326-6066.CIR-14-0114

  • Chu, Y., Yahr, A., Ayello, J., Van de Ven, C., & Cairo, M. (2014). Therapeutic effects of romidepsin, a histone deacetylase inhibitor (HDACI), alone and in combination with natural killer cells against pediatric Burkitt lymphoma. Pediatric Blood and Cancer, 61(S2), S138.

  • Chu, Y., Yahr, A., Ayello, J., Van De Ven, C., Barth, M., Czuczman, M., & Cairo, M. S. (2014). Anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells significantly mediate rituximab sensitive and resistant Burkitt lymphoma (BL) regression and improve survival in human BL xenografted NSG mice. Biology of Blood and Marrow Transplantation, 20(2 Suppl), S257.

  • Huang, X., Greene, J., Chu, Y., Hamby, C.Cairo, M. S., . . . Zhou, X. (2014). Chimeric antigen receptor (CAR) T cell immunotherapy for poor risk sarcomas. Biology of Blood and Marrow Transplantation, 20(2 Suppl), S184-S185.

  • Satwani, P., Bavishi, S., Saha, A., Zhao, F., Ayello, J., Chu, Y., . . . Cairo, M. S. (2014). Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. Cytotherapy, 16(10), 1431–1440. doi:10.1016/j.jcyt.2014.03.008